A phase I study of intra-anal artesunate (suppositories) to treat anal high-grade squamous intraepithelial lesions
Open Access
- 15 December 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (12) , e0295647
Abstract
Ablation or surgical excision is the typical treatment of anal high-grade squamous intraepithelial lesions (HSIL). Recurrences are common due to the persistence of underlying human papillomavirus (HPV) infection. Additional well-tolerated and effective non-surgical options for HPV-associated anal disease are needed. This 3+3 dose escalation Phase I clinical trial evaluated the safety and tolerability of artesunate suppositories in the treatment of patients with biopsy-proven HSIL. The maximal tolerated dose was 400 mg, administered in 3 cycles. All adverse events associated with the use 200- and 400-mg artesunate suppositories were Grade 1. At the 600-mg dose, patients experienced clinically significant nausea. Artesunate suppositories are a safe treatment option for anal HSIL.Keywords
Funding Information
- Frantz Viral Therapeutics
- Frantz Viral Therapeutics, LLC
This publication has 17 references indexed in Scilit:
- Intra-anal use of imiquimod: what is the clinical evidence?International Journal of STD & AIDS, 2019
- A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-anal 5% Imiquimod in HIV-1–Infected Men With High-Grade Squamous Intraepithelial LesionsDiseases of the Colon & Rectum, 2018
- Use of Artemisinin and its Derivatives to treat HPV-Infected/Transformed Cells and Cervical Cancer: A ReviewFuture Oncology, 2014
- Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trialThe Lancet Oncology, 2013
- Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial NeoplasiaJournal of the International Association of Physicians in AIDS Care, 2011
- Understanding the burden of human papillomavirus-associated anal cancers in the USCancer, 2008
- Drug‐resistant malaria − an insightThe FEBS Journal, 2007
- Rectal Administration of Artemisinin Derivatives for the Treatment of MalariaJAMA, 2007
- Dihydroartemisinin Is Cytotoxic to Papillomavirus-Expressing Epithelial Cells In vitro and In vivoCancer Research, 2005
- A Medicinal Chemistry Perspective on Artemisinin and Related EndoperoxidesJournal of Medicinal Chemistry, 2004